Literature DB >> 17873296

Smn depletion alters profilin II expression and leads to upregulation of the RhoA/ROCK pathway and defects in neuronal integrity.

Mélissa Bowerman1, Dina Shafey, Rashmi Kothary.   

Abstract

Spinal muscular atrophy (SMA) is the most common genetic disease resulting in infant mortality due to severe loss of alpha-motor neurons. SMA is caused by mutations or deletions of the ubiquitously expressed survival motor neuron (SMN) gene. However, why alpha-motor neurons of SMA patients are specifically affected is not clear. We demonstrate here that Smn knockdown in PC12 cells alters the expression pattern of profilin II, resulting in an increase in the neuronal-specific profilin IIa isoform. Moreover, the depletion of Smn, a known interacting partner of profilin IIa, further contributes to the increased profilin IIa availability. Altogether, this leads to an increased formation of ROCK/profilin IIa complex and an inappropriate activation of the RhoA/ROCK pathway, resulting in altered cytoskeletal integrity and a subsequent defect in neuritogenesis. This study represents the first description of a mechanism underlying SMA pathogenesis and highlights new targets for therapeutic intervention for this devastating disorder.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17873296     DOI: 10.1007/s12031-007-0024-5

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   2.866


  57 in total

1.  Different roles for RhoA during neurite initiation, elongation, and regeneration in PC12 cells.

Authors:  A Sebök; N Nusser; B Debreceni; Z Guo; M F Santos; J Szeberenyi; G Tigyi
Journal:  J Neurochem       Date:  1999-09       Impact factor: 5.372

2.  Mechanism responsible for the formation of focal swellings on injured neuronal processes using a novel in vitro model of axonal injury.

Authors:  Y Nakayama; Y Aoki
Journal:  Forensic Sci Int       Date:  2000-09-11       Impact factor: 2.395

3.  RhoA inhibits the nerve growth factor-induced Rac1 activation through Rho-associated kinase-dependent pathway.

Authors:  Y Yamaguchi; H Katoh; H Yasui; K Mori; M Negishi
Journal:  J Biol Chem       Date:  2001-03-15       Impact factor: 5.157

4.  Correlation between severity and SMN protein level in spinal muscular atrophy.

Authors:  S Lefebvre; P Burlet; Q Liu; S Bertrandy; O Clermont; A Munnich; G Dreyfuss; J Melki
Journal:  Nat Genet       Date:  1997-07       Impact factor: 38.330

Review 5.  GAP-43: an intrinsic determinant of neuronal development and plasticity.

Authors:  L I Benowitz; A Routtenberg
Journal:  Trends Neurosci       Date:  1997-02       Impact factor: 13.837

6.  Development of a gene therapy strategy for the restoration of survival motor neuron protein expression: implications for spinal muscular atrophy therapy.

Authors:  Christine J DiDonato; Robin J Parks; Rashmi Kothary
Journal:  Hum Gene Ther       Date:  2003-01-20       Impact factor: 5.695

7.  Spatio-temporal regulation of Rac1 and Cdc42 activity during nerve growth factor-induced neurite outgrowth in PC12 cells.

Authors:  Kazuhiro Aoki; Takeshi Nakamura; Michiyuki Matsuda
Journal:  J Biol Chem       Date:  2003-10-21       Impact factor: 5.157

8.  Gemin8 is a novel component of the survival motor neuron complex and functions in small nuclear ribonucleoprotein assembly.

Authors:  Claudia Carissimi; Luciano Saieva; Jennifer Baccon; Pieranna Chiarella; Alessio Maiolica; Alan Sawyer; Juri Rappsilber; Livio Pellizzoni
Journal:  J Biol Chem       Date:  2006-01-24       Impact factor: 5.157

9.  Knockdown of the survival motor neuron (Smn) protein in zebrafish causes defects in motor axon outgrowth and pathfinding.

Authors:  Michelle L McWhorter; Umrao R Monani; Arthur H M Burghes; Christine E Beattie
Journal:  J Cell Biol       Date:  2003-09-01       Impact factor: 10.539

10.  Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of beta-actin mRNA in growth cones of motoneurons.

Authors:  Wilfried Rossoll; Sibylle Jablonka; Catia Andreassi; Ann-Kathrin Kröning; Kathrin Karle; Umrao R Monani; Michael Sendtner
Journal:  J Cell Biol       Date:  2003-11-17       Impact factor: 10.539

View more
  54 in total

1.  Alpha-synuclein loss in spinal muscular atrophy.

Authors:  Gyula Acsadi; Xingli Li; Kelley J Murphy; Kathryn J Swoboda; Graham C Parker
Journal:  J Mol Neurosci       Date:  2010-07-17       Impact factor: 3.444

Review 2.  Spinal muscular atrophy: an update on therapeutic progress.

Authors:  Joonbae Seo; Matthew D Howell; Natalia N Singh; Ravindra N Singh
Journal:  Biochim Biophys Acta       Date:  2013-08-27

3.  Analysis of a read-through promoting compound in a severe mouse model of spinal muscular atrophy.

Authors:  Virginia B Mattis; Cheng-Wei Tom Chang; Christian L Lorson
Journal:  Neurosci Lett       Date:  2012-07-20       Impact factor: 3.046

4.  Laminin induced local axonal translation of β-actin mRNA is impaired in SMN-deficient motoneurons.

Authors:  Reena Rathod; Steven Havlicek; Nicolas Frank; Robert Blum; Michael Sendtner
Journal:  Histochem Cell Biol       Date:  2012-07-19       Impact factor: 4.304

5.  The Power of Human Protective Modifiers: PLS3 and CORO1C Unravel Impaired Endocytosis in Spinal Muscular Atrophy and Rescue SMA Phenotype.

Authors:  Seyyedmohsen Hosseinibarkooie; Miriam Peters; Laura Torres-Benito; Raphael H Rastetter; Kristina Hupperich; Andrea Hoffmann; Natalia Mendoza-Ferreira; Anna Kaczmarek; Eva Janzen; Janine Milbradt; Tobias Lamkemeyer; Frank Rigo; C Frank Bennett; Christoph Guschlbauer; Ansgar Büschges; Matthias Hammerschmidt; Markus Riessland; Min Jeong Kye; Christoph S Clemen; Brunhilde Wirth
Journal:  Am J Hum Genet       Date:  2016-08-04       Impact factor: 11.025

Review 6.  Advances in therapeutic development for spinal muscular atrophy.

Authors:  Matthew D Howell; Natalia N Singh; Ravindra N Singh
Journal:  Future Med Chem       Date:  2014-06       Impact factor: 3.808

Review 7.  Assays for the identification and prioritization of drug candidates for spinal muscular atrophy.

Authors:  Jonathan J Cherry; Dione T Kobayashi; Maureen M Lynes; Nikolai N Naryshkin; Francesco Danilo Tiziano; Phillip G Zaworski; Lee L Rubin; Jill Jarecki
Journal:  Assay Drug Dev Technol       Date:  2014-08       Impact factor: 1.738

Review 8.  Advances in therapy for spinal muscular atrophy: promises and challenges.

Authors:  Ewout J N Groen; Kevin Talbot; Thomas H Gillingwater
Journal:  Nat Rev Neurol       Date:  2018-02-09       Impact factor: 42.937

9.  Temporal requirement for SMN in motoneuron development.

Authors:  Le T Hao; Phan Q Duy; James D Jontes; Marc Wolman; Michael Granato; Christine E Beattie
Journal:  Hum Mol Genet       Date:  2013-03-03       Impact factor: 6.150

10.  Delivery of a read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal model.

Authors:  Virginia B Mattis; Allison D Ebert; Marina Y Fosso; Cheng-Wei Chang; Christian L Lorson
Journal:  Hum Mol Genet       Date:  2009-07-21       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.